Connect Biopharma is trading at $0.90, down 5.11%, amid biotech-sector and broader risk-off pressure.
- No new company-specific announcement explaining the October 8 decline surfaced.
- H.C. Wainwright reiterated its Buy rating and $7 target, which does not explain the drop.
- XBI was reported down more than 2% during the session, while rising oil prices and Treasury yields pressured stocks broadly. This points to sector and risk-off pressure, not a confirmed company-specific catalyst.